M&A Deal Summary |
|
|---|---|
| Date | 2022-06-27 |
| Target | Epizyme |
| Sector | Life Science |
| Buyer(s) | Ipsen |
| Sellers(s) | Bay City Capital |
| Deal Type | Going Private |
| Deal Value | 247M USD |
| Advisor(s) | Jefferies MTS Health Partners (Financial) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1929 |
| Sector | Life Science |
| Employees | 5,325 |
| Revenue | 3.3B EUR (2023) |
Ipsen is a research and development pharmaceutical company. It manufactures specialty pharmaceuticals and has a worldwide sales presence. Ipsen focuses on products in the gastro-enterology, neurology and cardiovascular therapeutic areas and has also developed specific expertise in some biotech niches such as endocrinology, oncology, neurology and hematology. Ipsen was founded in 1929 and is based in Boulogne-Billancourt, France.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 11 |
| Sector (Life Science) | 10 of 11 |
| Type (Going Private) | 1 of 1 |
| State (Massachusetts) | 2 of 3 |
| Country (United States) | 4 of 5 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 4 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-02-11 |
Ipsen - Consumer Healthcare Business
France Ipsen's Consumer Healthcare Business is a clinical specialty focusing on general medicine. It is usually the person’s first point of contact with medical personnel and also includes established brands such as Smecta, Forlax and Tanakan. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-01-09 |
Albireo
Boston, Massachusetts, United States Albireo is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase III trial in ALGS, an ongoing Phase III study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The company has also completed a Phase I clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. |
Buy | $952M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 63 of 63 |
| Sector (Life Science) | 46 of 46 |
| Type (Going Private) | 1 of 1 |
| State (Massachusetts) | 9 of 9 |
| Country (United States) | 60 of 60 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 8 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-30 |
Sunesis
South San Francisco, California, United States Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis was founded in 1998 and is based in South San Francisco, California. |
Sell | - |
